Bevacizumab Monotherapy for Temozolomide-Refractory Malignant Glioma

Japanese Journal of Neurosurgery - Japan
doi 10.7887/jcns.19.758
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The Japanese Congress of Neurological Surgeons

Related search

The Strategy for Enhancing Temozolomide Against Malignant Glioma

Frontiers in Oncology
Cancer ResearchOncology
2012English

Impact of Temozolomide on Immune Response During Malignant Glioma Chemotherapy

Clinical and Developmental Immunology
2012English

Gene Therapy for Malignant Glioma

Molecular and Cellular Therapies
2014English

Gene Therapy for Malignant Glioma

Japanese Journal of Neurosurgery
SurgeryNeurology
2003English

MicroRNA-93 Promotes the Malignant Phenotypes of Human Glioma Cells and Induces Their Chemoresistance to Temozolomide

Biology Open
BiochemistryAgriculturalGeneticsMolecular BiologyBiological Sciences
2016English

Addition of Lomustine for Bevacizumab-Refractory Recurrent Glioblastoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2014English

Phase II Study of Bevacizumab and Vorinostat for Patients With Recurrent World Health Organization Grade 4 Malignant Glioma

Oncologist
Cancer ResearchMedicineOncology
2017English

Polifeprosan 20, 3.85% Carmustine Slow-Release Wafer in Malignant Glioma: Evidence for Role in Era of Standard Adjuvant Temozolomide

Core Evidence
MedicineReviewsReferencesPharmacology
2012English

PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy